Analysts expect Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) to post earnings per share of ($1.47) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kodiak Sciences’ earnings. The highest EPS estimate is ($0.73) and the lowest is ($1.80). Kodiak Sciences reported earnings per share of ($0.98) during the […]
A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech says the failure is due to a subset of undertreated patients, but the results raise the stakes for the drug, its lead product candidate, in other eye diseases.